NewsFlash »

Innate Pharma And Celgene To Collaborate On Trial Combining Revlimid With IPH 2101 Therapies – Innate Pharma and Celgene will collaborate to evaluate the clinical potential of Celgene’s Revlimid (lenalidomide) plus Innate Pharma’s IPH 2101 in myeloma patients who have failed first-line therapy. In vitro studies on myeloma cell lines have shown that the two drugs may have a synergistic effect. Innate Pharma hopes to submit a request with the Food and Drug Administration in early 2010 to receive authorization to administer the drugs in humans. For more information, please see the Innate Pharma press release.  

Myeloma UK Launches The Innovative Myeloma Clinical Trial Network – The Clinical Trial Network will design and manage a portfolio of early phase trials of myeloma drugs by drawing on a collaboration of clinical specialists, researchers, pharmaceutical companies, and the National Health Service’s regulatory bodies. Eight research centers around the UK will be involved in the trials included in the portfolio. Myeloma patients will be able to take part in the trials at these centers. The first trials are expected to begin recruiting patients in early 2010. For more information, please visit the Myeloma UK Web site.

Peter Boyle Memorial Raises $700,000 For The IMF – The Third Annual Peter Boyle Memorial raised $700,000 for the International Myeloma Foundation. The event was launched three years ago by Boyle’s widow to help fund the battle against multiple myeloma. For more information, please visit the Los Angeles Times Web site.

News»